The relationship between vaping and erectile dysfunction has moved from speculation to measurable epidemiology in the space of a few years. Electronic nicotine delivery systems were introduced as a harm-reduction tool for combustible tobacco, and much of the early public health debate focused on lung injury and adolescent initiation. Sexual function received far less attention. That gap has begun to close. Large population datasets now report an association between daily e-cigarette use and self-reported erectile dysfunction, and laboratory work has identified a plausible vascular mechanism that connects the two. The evidence is not yet definitive, but it is coherent enough that it belongs in any serious conversation about men's vascular health.
The Vascular Basis of an Erection
An erection is a haemodynamic event before it is anything else. Sexual stimulation triggers the release of nitric oxide from cavernous nerve endings and, critically, from the endothelial cells lining the penile arteries and sinusoids. Nitric oxide activates guanylate cyclase, raising intracellular cyclic GMP, which relaxes the smooth muscle of the helicine arteries. Blood inflow rises sharply, the expanding sinusoids compress the subtunical venules, and outflow is passively restricted. The entire sequence depends on a healthy endothelium producing adequate nitric oxide on demand.
This is why erectile dysfunction is so often a vascular symptom rather than a purely sexual one. The penile arteries are narrow — roughly 1 to 2 mm in diameter — compared with the coronary arteries at 3 to 4 mm. Diffuse endothelial injury therefore tends to become clinically apparent in the penis before it announces itself in the heart. Any exposure that degrades endothelial nitric oxide bioavailability, whether through oxidative stress, inflammation, or enzymatic dysfunction, is biologically positioned to impair erectile function. That principle is the reason researchers began asking about e-cigarettes in the first place.
What the PATH Study Found About Vaping and Erectile Dysfunction
The most substantial human data to date come from the Population Assessment of Tobacco and Health study, a nationally representative United States cohort. El-Shahawy and colleagues analysed Wave 4 data, collected between 2016 and 2018, covering male participants aged 20 years and older who answered a question about erectile dysfunction [1].
The headline finding was a dose-related signal. Among current daily users of electronic nicotine delivery systems, the adjusted odds of reporting erectile dysfunction were 2.24 times those of never users (95% CI 1.50–3.34). The investigators then restricted the sample to men aged 20 to 65 with no prior cardiovascular disease diagnosis — the group in which confounding by established vascular illness is least likely — and the association strengthened rather than weakened, to an adjusted odds ratio of 2.41 (95% CI 1.55–3.74). Erectile dysfunction was reported by 20.7% of the full sample and 10.2% of the restricted sample. Current e-cigarette use was reported by 4.8% and 5.6% of the two samples respectively, with daily use at 2.1% and 2.5%.
Several caveats deserve emphasis. The design is cross-sectional, so temporal sequence cannot be established and reverse causation cannot be excluded. Erectile dysfunction was self-reported rather than measured with a validated instrument such as the International Index of Erectile Function. Many daily vapers are former or dual smokers, and residual confounding by prior combustible tobacco exposure is difficult to eliminate statistically. The study attracted published correspondence contesting its interpretation. What the analysis establishes is an association of meaningful size that persisted in the lowest-risk subgroup — not proof that vaping causes erectile dysfunction.
Why E-Cigarette Aerosol Damages the Endothelium
The epidemiological signal is more credible because an independent line of laboratory evidence predicts it. El-Mahdy and colleagues demonstrated that chronic e-cigarette exposure produces vascular endothelial dysfunction through two linked mechanisms: activation of NADPH oxidase and uncoupling of endothelial nitric oxide synthase [2].
The second of these is particularly relevant to erectile physiology. When endothelial nitric oxide synthase is uncoupled — typically through oxidation of its tetrahydrobiopterin cofactor — the enzyme stops producing nitric oxide and begins producing superoxide instead. The cell does not merely lose a vasodilator; it gains an oxidant that scavenges whatever nitric oxide remains, forming peroxynitrite. A system designed to deliver vasodilation on demand is converted into a source of oxidative stress. In a vascular bed as small and as dependent on nitric oxide as the penile circulation, that conversion has obvious functional consequences.
Human work supports the animal findings. Mohammadi and colleagues reported that chronic e-cigarette use impairs endothelial function at both physiological and cellular levels, with measurable changes in vascular reactivity among users [3]. Pincus and colleagues reviewed this literature specifically through the lens of sexual medicine and concluded that e-cigarette-associated endothelial damage represents a plausible mechanism for erectile dysfunction, while noting that direct clinical evidence remained limited at the time of writing [4]. Nicotine itself contributes through sympathetic activation and acute vasoconstriction, but the aerosol carries additional candidates — carbonyls generated by heating propylene glycol and vegetable glycerin, flavouring aldehydes, and trace metals from the heating coil.
Is Vaping Safer Than Smoking for Erectile Function?
This is the question most men actually want answered, and the honest response is that the comparison is less settled than either side of the public debate suggests.
The case against combustible cigarettes is not in dispute. Smoking is among the most consistently replicated modifiable risk factors for erectile dysfunction, acting through endothelial injury, accelerated atherosclerosis, and chronic oxidative stress. Corona and colleagues reviewed the effects of tobacco on male sexual and reproductive health and concluded that available evidence showed e-cigarettes to be considerably less dangerous than traditional tobacco use, with preliminary animal data suggesting a milder effect on erectile function and sperm parameters [5].
"Less harmful than smoking" and "harmless" are, however, different claims. The PATH association appeared in daily users after adjustment, and the mechanistic data show real endothelial injury rather than none. The most defensible reading of the current evidence is that switching from cigarettes to vaping probably reduces vascular risk, while taking up vaping as a non-smoker almost certainly adds risk that would otherwise not exist. For men who already have erectile symptoms, nicotine exposure in any delivery format is a reasonable target for modification. Our wider blog library covers the other major vascular contributors in more detail.
Reversibility, Confounders, and Clinical Context
Endothelial dysfunction is not necessarily permanent, and this is the most useful thing a clinician can tell a patient. Harte and Meston followed men through a smoking cessation programme and documented improvements in physiological sexual arousal and erectile response among those who successfully quit, with the clearest gains in men who achieved sustained abstinence [6]. The cavernosal endothelium retains considerable capacity for recovery once the oxidative insult is withdrawn. Some men experience noticeable improvement within weeks; others require months, and those with established atherosclerotic disease may see only partial recovery.
Vaping should also be placed in proportion. In the PATH analysis, age was by far the dominant predictor — men aged 65 and over had an adjusted odds ratio of 17.4 relative to men aged 20 to 24 — and a history of cardiovascular disease carried an odds ratio of 1.39, while physical activity was associated with lower odds of erectile dysfunction [1]. Nicotine exposure is one modifiable input among several. A man who vapes daily, sleeps poorly, carries central adiposity, and has untreated hypertension or dyslipidaemia is not facing a vaping problem. He is facing a vascular problem with multiple contributors, and new-onset erectile dysfunction in that context warrants a proper cardiometabolic workup rather than a prescription alone.
Conclusion
The available evidence links daily e-cigarette use to roughly twice the odds of erectile dysfunction in a large representative sample, and laboratory work provides a credible mechanism in NADPH oxidase activation and endothelial nitric oxide synthase uncoupling. The data remain cross-sectional and the comparison with combustible tobacco still favours vaping, so the appropriate conclusion is caution rather than alarm. Clinical studies suggest that nicotine exposure in any form is worth treating as a modifiable vascular risk factor, particularly in men who are already experiencing changes in erection quality. Erectile dysfunction is frequently the earliest clinical signal that endothelial health is deteriorating, and it deserves to be investigated as such rather than dismissed.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com, including on-demand formulations such as Red Pill.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
El-Shahawy O, Shah T, Obisesan OH, Durr M, Stokes AC, Uddin I, Pinjani R, Benjamin EJ, Mirbolouk M, Osei AD, Loney T, Sherman SE, Blaha MJ. Association of E-Cigarettes With Erectile Dysfunction: The Population Assessment of Tobacco and Health Study. American Journal of Preventive Medicine. 2022;62(1):26-38. doi:10.1016/j.amepre.2021.08.004
El-Mahdy MA, Ewees MG, Eid MS, Mahgoup EM, Khaleel SA, Zweier JL. Electronic cigarette exposure causes vascular endothelial dysfunction due to NADPH oxidase activation and eNOS uncoupling. American Journal of Physiology-Heart and Circulatory Physiology. 2022;322(4):H549-H567. doi:10.1152/ajpheart.00460.2021
Mohammadi L, Han DD, Xu F, Huang A, Derakhshandeh R, Rao P, Whitlatch A, Cheng J, Keith RJ, Hamburg NM, Ganz P, Hellman J, Schick SF, Springer ML. Chronic E-Cigarette Use Impairs Endothelial Function on the Physiological and Cellular Levels. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(11):1333-1350. doi:10.1161/ATVBAHA.121.317749
Pincus J, Sandoval V, Dick B, Sanekommu G, Rajasekaran R, Ramasamy R, Raheem O. E-Cigarette-Associated Endothelial Damage: A Potential Mechanism for Erectile Dysfunction. Sexual Medicine Reviews. 2022;10(1):168-173. doi:10.1016/j.sxmr.2021.01.003
Corona G, Sansone A, Pallotti F, Ferlin A, Pivonello R, Isidori AM, Maggi M, Jannini EA. People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. Journal of Endocrinological Investigation. 2020;43(10):1391-1408. doi:10.1007/s40618-020-01257-x
Harte CB, Meston CM. Association between smoking cessation and sexual health in men. BJU International. 2012;109(6):888-896. doi:10.1111/j.1464-410X.2011.10503.x
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.